logo 胸外文献每日监控
2026年8月13日星期四
Weekly Review

胸外文献周报

2026.08.03 – 08.09
本周收录 34 篇
肺癌 29 篇
临床研究

本周14项临床研究从肺癌风险分层、围术期管理、晚期系统治疗及罕见分子亚型等维度提供了新证据。在风险与监测方面，[5]基于SUMMIT前瞻性队列中13,000名吸烟者里的511例同时使用雪茄/烟斗/小雪茄者，提示非卷烟烟草制品可能叠加增加肺癌风险并影响LDCT筛查资格；[1]在5650例I-III期NSCLC根治术后退伍军人队列中，采用时变主动监测依从性分析发现，较高的监测依从性与更好生存相关；[8]通过56例吸烟、56例不吸烟肺癌患者与78名健康对照的比较，探索了循环细菌DNA及炎症细胞因子与不吸烟肺癌的关联；[13]对1200余例肺癌全基因组测序显示18.9%存在ecDNA，MDM2扩增与总生存变差相关，且与全基因组倍增关联，提示基因组不稳定性在非吸烟肺癌中的作用。在围术期治疗方面，[9]报告了CHIO3单臂II期试验中37例可切除N2+ NSCLC患者接受含铂双药联合度伐利尤单抗新辅助治疗，其中30例完成手术，并报告了术式、切缘与并发症等手术结果；[10]利用美国退伍军人健康管理局数据库刻画了接受化疗免疫治疗的cStage IB-III N2患者未进展至手术人群的退出模式与临床特征；[7]在340例IB期EGFR突变NSCLC真实世界队列中显示，辅助EGFR-TKI较未用药显著改善长期生存。在晚期治疗领域，[4]利用法国ESME国家队列验证了广泛期小细胞肺癌二线化疗的疗效不因一线免疫治疗暴露而改变；[11]多中心回顾性研究纳入450例二线nivolumab的转移性NSCLC，发现合并糖尿病者与无糖尿病者的PFS、OS、ORR无显著差异，但3-4级免疫相关不良事件发生率更高；[12]在109例一线EGFR突变NSCLC患者中，阿美替尼的中位PFS优于奥希替尼（34.4 vs 26.9个月，HR 0.52）。在特殊人群与分子事件方面，[2]分析了111例NSCLC相关胸腔积液的免疫特征，比较了细胞学阳性与阴性积液的生化及细胞因子谱；[3]报道了5例Li-Fraumeni综合征相关肺腺癌，确诊中位年龄34岁，多为不吸烟者且均检出EGFR活化突变，其中1例对lazertinib联合amivantamab持续应答；[6]个案显示一例肺肉瘤样癌携带非经典MET外显子14剪接变异（初判VUS），经RNA测序确认跳跃后对卡马替尼产生快速持久应答；[14]在97例BRAF融合NSCLC中鉴定出104个融合和53个伙伴基因，从头与获得性病例的伙伴基因分布不同，为BRAF融合靶向治疗提供了依据。这些真实世界与分子层面的证据共同更新了肺癌个体化管理的认识。

AI/ML

本周 4 项人工智能/机器学习研究[15-18]从影像预测、药物反应、靶点发现与风险分层等维度拓展了肺癌及其他肿瘤的智能化应用。[15]提出多模态深度学习网络 DAFNet，基于术前全肺 CT 自动预测肺腺癌气腔播散（STAS），无需手动勾画肿瘤；在双中心 1164 例患者（511 例 STAS 阳性）的回顾性队列中，以 70:30 划分训练/测试集，测试集 AUROC 达 0.90（95% CI 未完整报告），为术前无创识别高危侵袭模式提供了全自动工具。[16]介绍以基因必需性为核心的药物反应预测平台 DrGee，其内置 DeepEEAA 模型整合基因表达、必需性、药物-蛋白质亲和力及药物-基因关联，独立细胞系数据上预测 IC50 的 R²=0.764、MSE=0.9345，优于近期深度学习方法；并在 95-D 肺癌细胞系中优先推荐 4 种候选药物，其中 BI-97C1 和 trimetrexate 经体外实验及小鼠异种移植验证，展示了从计算到实验的闭环能力。[17]报道 AI 生物学家 XunZi，整合逻辑推理和多模态数据融合，可自主生成可测试的疾病修饰靶点假设；其经 2440 万篇论文及 613.6 TB 多源数据训练，覆盖 21,008 个人类基因和 5,850 种疾病，在帕金森病中识别出 CHK2 和 IRAK4 激酶异常激活，且 Chk2 抑制可挽救模型小鼠多巴胺能神经元丢失和运动缺陷，提示该方法同样具有扩展至肺癌靶点发现的潜力。[18]针对肺癌一线免疫治疗后的静脉血栓栓塞（VTE）风险，基于双中心 2300 例患者构建 6 个月预测模型，并纳入独立外部中心 491 例验证；Lasso-logistic 模型在内部测试集 AUC 0.692、外部测试集 AUC 0.728，均优于 Khorana、Padua、PROTECHT、ONKOTEV 及 COMPASS-CAT 评分（p<0.05），高危组累积 VTE 发生率显著高于低危组（12.3% vs 4.8%），为免疫治疗人群的 VTE 个体化筛查提供了可操作的机器学习工具。总体来看[15-18]表明，AI/ML 在肺癌的影像表型识别、药物敏感性预测、靶点假设生成及治疗相关并发症风险分层中均展现出临床应用价值，但多数研究为回顾性设计，前瞻性验证与外部泛化仍是未来转化重点。

基础研究

本周10项基础研究从分子机制、免疫微环境与治疗策略更新了肺癌转化证据。[19]对15,765例肺腺癌组织的测序显示PDLIM2高表达更常见于局部活检(73.1% vs 53.0%)，伴EGFR突变增加和免疫浸润升高。[20]CRISPR-Cas9敲除证实NCCRP1缺失可克服肺腺癌免疫逃逸并抑制小鼠肿瘤生长；[21]发现sotorasib经STAT1诱导M1C，通过NF-κB介导EMT驱动KRAS G12C耐药，靶向M1C可逆转耐药；[22]显示RanBP2经LRSAM1 SUMO化稳定SLC7A1抑制铁死亡，高表达提示预后不良；[24]阐明RAB32-USP13轴维持TOM40线粒体定位，敲除在体内外抑制NSCLC进展；[25]证明CHAF1A以ATM相关方式富集于DNA损伤位点，经RAD51装载促进同源重组导致放射抗性。[23]在肥胖/瘦弱小鼠及73例患者中显示自愿运动可改善肥胖驱动的肺免疫抑制。[26]对5例新辅助免疫治疗肺鳞癌的28个样本分析显示肿瘤远端纵隔淋巴结富含祖细胞耗竭CD8+T细胞并与肿瘤终末耗竭T细胞共享克隆谱系；[27]开发Stereo-XCR-seq在11例肺腺癌中定位异位类生发中心生态位；[28]人源化小鼠显示SCLC-inflamed亚型T细胞浸润最高并获得PD1、CD39、TOX耗竭表型。这些结果强调了铁死亡、DNA修复、线粒体稳态及免疫检查点通路作为联合治疗靶点的潜力。

综述Meta

本篇[29]为系统综述与Meta分析，旨在明确FDG PET-CT对T1部分实性肺腺癌淋巴结分期的诊断准确性。研究遵循PICO框架进行系统检索，并采用预先定义的纳入与排除标准筛选文献，使用QUADAS-2工具评估纳入研究的偏倚风险。汇总各研究数据后，以森林图与HSROC曲线呈现FDG PET-CT的敏感性与特异性，并与胸部CT进行对比。摘要未报告纳入研究数量、患者总数及汇总的敏感性和特异性具体数值，也未给出置信区间。作者指出，肺腺癌呈磨玻璃或部分实性表现时生长缓慢、FDG亲和力低，回顾性证据提示此类T1病灶中FDG PET-CT分期价值有限；而NICE指南仍推荐FDG PET-CT以确认适合根治性治疗患者的局限性疾病。该Meta分析的结果将为部分实性肺癌的淋巴结分期策略提供证据，但受限于原始研究的回顾性设计及可能的异质性，其临床适用性仍需前瞻性验证。

食管癌 4 篇
基础研究

本周 4 项基础研究[30-33]从不同角度揭示了食管鳞状细胞癌(ESCC)进展、免疫逃逸与治疗耐药的分子机制。[30]发现GTP结合蛋白GEM在ESCC中高表达并与抗PD-L1治疗反应不良相关:肿瘤细胞GEM通过诱导SERPINE1分泌、经巨噬细胞LRP1受体驱动替代激活,抑制CD8+ T细胞浸润与杀伤功能;机制上GEM通过MKK3-RACK1-p38-MEF2A级联上调SERPINE1,为克服免疫治疗耐药提供了靶向GEM或SERPINE1的潜在策略。[31]报道锌指蛋白ZBED2通过相分离形成核凝聚体,增强HSP90AA1转录,促进HSP90AA1与整合素连接激酶(ILK)结合并抑制其泛素化降解,进而上调PD-L1并诱导CD8+ T细胞耗竭,驱动ESCC转移与免疫逃逸;该研究将相分离机制与肿瘤微环境免疫抑制联系起来。[32]聚焦慢性应激对代谢的调控,基于ESCC患者血清非靶向代谢组学发现应激相关特征患者中磷酸戊糖途径(PPP)富集且肾上腺素升高;机制上,应激激活β2-肾上腺素能受体(ADRB2),通过竞争性置换VHL稳定MYCBP,增强MYC转录活性并上调G6PD和TKT等PPP关键酶,同时依赖RNMT的m7G帽修饰增加ADRB2自身丰度,形成正反馈促进肿瘤进展,提示干预ADRB2信号或m7G修饰可能阻断应激驱动的代谢重编程。[33]则探讨RNA编辑酶ADAR1在放疗抵抗中的作用,ADAR1在ESCC中高表达且与新辅助放化疗反应不良相关;ADAR1缺失通过全转录组RNA编辑分析确定C16orf46为功能性靶点,减少C16orf46编辑并促进gasdermin E(GSDME)介导的焦亡,从而在体外和异种移植模型中抑制肿瘤生长并增强放射敏感性。综合[30-33],这些研究从免疫微环境重编程、相分离、应激代谢和RNA编辑等维度提供了ESCC新型治疗靶点,为联合免疫治疗与放疗的精准策略奠定了机制基础。

气胸·外伤·胸壁 1 篇
临床研究

本周临床研究领域仅纳入 1 项技术报告[34]，聚焦肋间疝（IH）合并肋缘破裂（CMR）的漏诊问题与新型手术修复策略。该研究为单中心病例系列，共报告 3 例 IH 患者，其中首例在初次 IH 手术失败后才经术后影像确诊 CMR，后两例则因临床怀疑指数提高而在术前即获得早期诊断，提示 CMR 在 IH 患者中易被忽视、需结合全面影像学及数字重建技术提高检出率[34]。所有 3 例患者均采用创新技术修复 CMR：将钛棒压接于可旋转连接器，再安装在钛肋夹上，从而重建肋缘完整性并同时处理肋间缺损。术后所有患者均获得成功修复，但摘要未报告随访时间、并发症发生率或长期功能结果等具体数值[34]。该技术为复发性或复杂 IH 合并 CMR 提供了一种新的手术选项，但其推广价值仍需更大样本及前瞻性对照验证，作者也强调早期识别和标准化分类是改善预后的关键[34]。

参考文献

  1. [1] Amanda Immidisetti, Nicole Lin, Julie Wu, Scott V Adams, Ntemena Kapula, Steven M Asch, Steven B Zeliadt, Alex H S Harris, Ann Leung, Summer Han, Leah Backhus Post-Treatment Imaging in Lung Cancer Patients: Adherence to Surveillance Guidelines Is Associated with Improved Survival in a Longitudinal Cohort. The Journal of Thoracic and Cardiovascular Surgery 2026 Aug 04 doi:10.1016/j.jtcvs.2026.07.016  ·  IF 4.7 · Q1 PubMed↗
  2. [2] Matilde Lombardi, Michael Gerckens, Gülümser Hale Alkan, Daria Khmelovska, Lena Gaedtke, Nicole Weiß, Georg Mertens, Johannes Krämer, Thomas Melzer, Gabriela Leuschner, A Önder Yildirim, Nikolaus Kneidinger, Jürgen Behr, Gabriel Mircea Stoleriu, Carlo Mümmler, Diego Kauffmann-Guerrero Immune signatures in NSCLC associated pleural effusions and implications for prognosis. Lung Cancer 2026 Aug 07 doi:10.1016/j.lungcan.2026.109563  ·  IF 5.3 · Q1 PubMed↗
  3. [3] Kota Ishioka, Makoto Nishio, Hironori Ninomiya, Noriko Yanagitani, Yoshiaki Amino, Yosuke Matsuura, Masayuki Nakao, Asami Kuga, Keika Kaneko, Hiromi Arakawa, Yuko Minoura, Akito Dobashi, Eri Habano, Sakae Okumura, Mingyon Mun, Arisa Ueki Clinical characteristics and management of Li-Fraumeni syndrome-associated lung cancer. Lung Cancer 2026 Aug 03 doi:10.1016/j.lungcan.2026.109559  ·  IF 5.3 · Q1 PubMed↗
  4. [4] E Gobbini, M H Diallo, C Clément-Duchene, C Chouaid, S Hiret, C Audigier-Valette, A Bizieux, D Debieuvre, X Quantin, Y Le Guen, A Lemoine, L Falchero, J Remon-Masip, L Bosquet, M Pérol, N Girard Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort. ESMO Open 2026 Aug 07 doi:10.1016/j.esmoop.2026.108324  ·  IF 10.6 · Q1 PubMed↗
  5. [5] Simran Vaja, Jennifer L Dickson, Carolyn Horst, Monica L Mullin, Amyn Bhamani, Andrew Creamer, Helen Hall, Chuen R Khaw, Ruth Prendecki, Priyam Verghese, Sophie Tisi, John McCabe, Esther Arthur-Darwka, Neal Navani, Anand Devaraj, Arjun Nair, SUMMIT consortium, Sam M Janes, Allan Hackshaw The effect of cigar, cigarillo and pipe smoking on lung cancer risk and screening eligibility. British Journal of Cancer 2026 Aug 07 doi:10.1038/s41568-021-00423-4  ·  IF 7.8 · Q1 PubMed↗
  6. [6] Hyung-Joo Oh, Yoo-Duk Choi, Yoon-La Choi, Ha-Young Park, Joon-Young Yoon, Jang-Hyeon Kim, Jung-Hwan Lim, Cheol-Kyu Park, In-Jae Oh, Young-Chul Kim A Noncanonical MET Exon 14 Splice-Site Variant in Pulmonary Sarcomatoid Carcinoma With Response to Capmatinib. Thoracic Cancer 2026 Aug doi:10.1111/1759-7714.70371  ·  IF 2.6 · Q2 PubMed↗
  7. [7] Mu-Zi Yang, Zeng-Hao Chang, Jing-Sheng Cai, Xue Hou, Hao-Xian Yang De-escalation of Adjuvant EGFR-TKI in Stage IB EGFR-Mutated Non-small-cell Lung Cancer: A Real-World Study. Annals of Surgical Oncology 2026 Aug 06 doi:10.1158/2159-8290.CD-21-1486  ·  IF 3.8 · Q1 PubMed↗
  8. [8] Pushpa Dhilipkannah, Feng Jiang Coordinated microbial-inflammatory associations in never-smoking lung cancer. Lung Cancer 2026 Aug 03 doi:10.1016/j.lungcan.2026.109561  ·  IF 5.3 · Q1 PubMed↗
  9. [9] Linda W Martin, Xiaofei Wang, David Kozono, James Urbanic, Ankit Bharat, Mark Crye, Mark K Ferguson, Samuel S Kim, Jason Wallen, Jyoti D Patel, Thomas E Stinchcombe CHIO3: CHemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B (N2) Non-Small Cell Lung Cancer: Surgical Outcomes. The Annals of Thoracic Surgery 2026 Aug 05 doi:10.1016/j.athoracsur.2026.07.041  ·  IF 5.3 · Q1 PubMed↗
  10. [10] Whitney S Brandt, Daniel B Eaton, Nahom Seyoum, Theodore S Thomas, Nikki Rossetti, Su-Hsin Chang, Yan Yan, Martin W Schoen, Molly C Tokaz, Daniel Kreisel, Ruben G Nava, Bryan F Meyers, Benjamin D Kozower, Brendan T Heiden, Varun Puri Dropout after Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer in the Veterans Health Administration. The Annals of Thoracic Surgery 2026 Aug 05 doi:10.1016/j.athoracsur.2026.07.031  ·  IF 5.3 · Q1 PubMed↗
  11. [11] Emre Çakır, Didem Divriklioğlu, Deniz Can Güven, Gamze Serin Özel, Oğuzhan Yıldız, Gamze Emin, Merve Keskinkılıç, Yeşim Ağyol, Onur Yazdan Balçık, Nagihan Kolkıran, Hale Gülçin Yıldırım Doğan, Pervin Can Şancı, Özge Yalıcı, Teoman Şakalar, Yurdagül Danacı, Yakup Düzköprü, Canan Yıldız, Mesut Yılmaz, İlhan Hacıbekiroğlu, Bülent Erdoğan, Saadettin Kılıçkap, Gamze Gököz Doğu, Melek Karakurt Eryılmaz, Atila Yıldırım, İlhan Öztop, İbrahim Vedat Bayoğlu, Şahnura Uzuntaş, Atike Pınar Erdoğan, Emir Çelik, Devrim Çabuk, Erdoğan Selçuk Şeber, Zehra Sadak Öcal, Hacer Demir Diabetes Increases Immunotherapy-Related Toxicity but Not Efficacy in Metastatic Non-Small Cell Lung Cancer: A Multicenter Retrospective Study. International Journal of Cancer 2026 Aug 06 doi:10.1002/ijc.70688  ·  IF 4.9 · Q2 PubMed↗
  12. [12] Jinxia Wang, Ping Qi, Jinhua Li, Na Wang, Caihong Fu, Lixin Liu, Shuping Li, Xiao Li, Xiaoming Hou, Hui Qiao Aumolertinib Versus Osimertinib as First-Line Treatment for EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Multicenter Study. International Journal of Cancer 2026 Aug 04 doi:10.1002/ijc.70617  ·  IF 4.9 · Q2 PubMed↗
  13. [13] Azhar Khandekar, Phuc H Hoang, Jens Luebeck, Marcos Díaz-Gay, Wei Zhao, John P McElderry, Caleb Hartman, Mona Miraftab, Olivia W Lee, Kara M Barnao, Kristine Jones, Amy Hutchinson, Belynda Hicks, Erik N Bergstrom, Yang Yang, Martin A Nowak, Nathaniel Rothman, Angela C Pesatori, Dario Consonni, Robert Homer, Marina K Baine, Lynette M Sholl, Philippe Joubert, Charles Leduc, William D Travis, Soo-Ryum Yang, Qing Lan, David C Wedge, Lixing Yang, Stephen J Chanock, Tongwu Zhang, Ludmil B Alexandrov, Maria Teresa Landi Examining the role of extrachromosomal DNA in lung cancer. Journal of the National Cancer Institute 2026 Aug 05 doi:10.1093/jnci/djag273  ·  IF 7.7 · Q1 PubMed↗
  14. [14] Kai Wang, Chao Yi, Xiong Ning, Dalin Xiong, Song Wang, Xiaoying Wu, Hua Bao, Yuan Jiang, Hongyu Deng, Faqing Tang BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer. Lung Cancer 2026 Jul 30 doi:10.1016/j.lungcan.2026.109556  ·  IF 5.3 · Q1 PubMed↗
  15. [15] Jirui Guo, Shizheng Qiu, Huanyu You, Huiting Zhang, Haozheng Liang, Ping Wang, Zhishuai Zhang, Wei Meng, Yang Hu DAFNet: A multi-modal deep learning model based on whole-lung CT for the automated prediction of the air space spread of lung adenocarcinoma. Lung Cancer 2026 Aug 01 doi:10.1016/j.lungcan.2026.109557  ·  IF 5.3 · Q1 PubMed↗
  16. [16] Hongtu Cui, Xiaohui Du, Haixia Guo, Zhen Liao, Bingying Wang, Xiang Lian, Ji-Yun Zhang, Xing Lu, Dongdong Zhang, Anqiang Ye, Jing Feng, Jing Li, Zhenshun Cheng, Feng-Biao Guo Essentiality-driven prediction of anticancer drug responses in preclinical and clinical contexts. iScience 2026 Aug 21 doi:10.1093/nar/gkv007  ·  IF 4.5 · Q1 PubMed↗
  17. [17] Xinhe Huang, Junhong Qin, Fei Tang, Chenyu Yang, Linhua Xu, Junfen Wei, Dan Liu, Kang Chen, Chi Zhang, Miaomiao Chen, Yujie Gou, Jiayi Zhang, Yongze Ma, Lin Zhao, Yingfeng Tu, Peng Lei, Yu Xue, Da Jia XunZi, an AI biologist, reveals disease-modifying targets. Nature Biomedical Engineering 2026 Aug 04 doi:10.1126/scitranslmed.abp9352  ·  IF 26.3 · Q1 PubMed↗
  18. [18] Shengyuan Wang, Siwan Wen, Mengmeng Zhao, Wanzhen Li, Minglei Yang, Chang Chen, Xianghuai Xu Enhancing venous thromboembolism risk prediction after immunotherapy for lung cancer. iScience 2026 Aug 21 doi:10.1016/j.isci.2026.116890  ·  IF 4.5 · Q1 PubMed↗
  19. [19] Karam Ashouri, Fan Sun, Harris Krause, Andrew Elliott, Stephen V Liu, Patrick C Ma, Balazs Halmos, Gutian Xiao, Ari Vanderwalde, Jorge J Nieva, Zhaoxia Qu Exploring PDLIM2 as a prognostic biomarker and therapeutic target in lung adenocarcinoma. British Journal of Cancer 2026 Aug 08 doi:10.1016/j.jtho.2024.09.1381  ·  IF 7.8 · Q1 PubMed↗
  20. [20] Lu Liu, Shihao Qi, Liye Shao, Junyang Cai, Qingqing Zeng, Xu Jiang, Fang Ma, Weiwei Lin Loss of NCCRP1 overcomes immune evasion in lung adenocarcinoma. Journal for ImmunoTherapy of Cancer 2026 Aug 05 doi:10.1136/jitc-2026-015072  ·  IF 11.7 · Q1 PubMed↗
  21. [21] Shinkichi Takamori, Naoki Haratake, Atrayee Bhattacharya, Hiroki Ozawa, Keisuke Shigeta, Mai Onishi, Kentaro Nonaka, Takefumi Komiya, Hiroki Komatsuda, Tomoyoshi Takenaka, Tomoharu Yoshizumi, Chendi Li, Jiehui Deng, Aaron N Hata, Kwok K Wong, Mark D Long, Donald Kufe M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors. Oncogene 2026 Aug 05 doi:10.1172/jci.insight.190924  ·  IF 9.1 · Q1 PubMed↗
  22. [22] Shiwei Guo, Yu Zeng, Qinfen Zhang, Xiaohe Zhao, Haixia Jin, Baihui Li, Meng Shen, Qing Yang, Lili Yang RanBP2 promotes ferroptosis resistance and compromises therapeutic response by stabilizing SLC7A1 through LRSAM1 SUMOylation and ubiquitination in lung adenocarcinoma. Cell Death & Differentiation 2026 Aug 05 doi:10.1016/j.redox.2022.102276  ·  IF 13.6 · Q1 PubMed↗
  23. [23] Randall Smith, Kayleigh Erickson, Deschana Washington, Robert Zollo, Sukumar Kalvapudi, Yeshwanth Vedire, Cara Petrucci, Vethanayagam Rr, Hua-Hsin Hsiao, Spencer Rosario, Joseph Barbi, Sai Yendamuri, Andrew Ray Exercise Modulates Adiposity-induced Immune Dysfunction in NSCLC and Non-tumor-Bearing Lungs: Implications for Lung Cancer Therapy and Interception. Annals of Surgery 2026 Aug 06 doi:10.1097/SLA.0000000000007151  ·  IF 7.4 · Q1 PubMed↗
  24. [24] Hong-Xu Li, Yi-Ting Wei, Hu Gan, Han-Yue Zhang, Xin-Lin Qu, Yijie Zhang, Xiaoping Miao, Bo Zhong, Dandan Lin The RAB32-USP13 axis facilitates TOM40 mitochondrial localization to promote non-small cell lung cancer progression. Cell Death & Differentiation 2026 Aug 04 doi:10.1016/j.cellin.2026.100298  ·  IF 13.6 · Q1 PubMed↗
  25. [25] Ruru Wang, Yao Hou, Jie Zhang, Zhicheng Yao, Xipeng Zhao, Bin Chen, Jie Zhang, Shenglan Zhou, Guoping Zhao, Feng Xu CHAF1A promotes RAD51 loading and homologous recombination to drive tumor radioresistance. Oncogene 2026 Aug 04 doi:10.3389/fgene.2023.1108004  ·  IF 9.1 · Q1 PubMed↗
  26. [26] Bin Zhang, Pengpeng Zhang, Zhanshuo Zhang, Jiping Xie, Xiaonan Cui, Chen Chen, Qiang Zhang, Yuechen Cui, Leina Sun, Shuo Wang, Xinyi Wu, Wuhao Huang, Yue Li, Yao Tang, Wei Wei, Meng Wang, Jinpu Yu, Changli Wang, Zhenfa Zhang, Dongsheng Yue Tumor-distal mediastinal lymph nodes harbor tumor-related progenitor exhausted T cells in lung cancer after neoadjuvant chemoimmunotherapy. Cell 2026 Aug 03 doi:10.1016/j.xcrm.2026.102964  ·  IF 45.1 · Q1 PubMed↗
  27. [27] Xiaojuan Zhan, Mengye Huang, Yang Zhang, Zhong Liu, Chengwu Liu, Yanying Guo, Yi Liu, Wenwen Zhou, Yixin Yan, Hui Zeng, Yingqi Dong, Xuan Dong, Xiaoyu Chen, Haohang Yang, Rong Ma, Fan Zhu, Xubin Zheng, Xinxing Li, Sen Hou, Zhidong Gao, Jinwen Yin, Francis Ka-Ming Chan, Qin Wu, Senyi Deng, Yin Yao, Shengbao Suo, Chuanyu Liu, Longqi Liu, Xun Xu, Yong Hou, Haoran Tao, Xinlei Ai, Yuliang Dong, Tao Zeng, Hanyong Sun, Young Li, Li Zuo, Hua Wang, Xin Liu, Zhifang Wu, Jingying Zhou, Zexian Zeng, Yu Feng Uncovering ectopic GC-like niches for tumor reactive lymphocyte priming in lung adenocarcinoma using Stereo-XCR-seq. Nature Communications 2026 Aug 03 doi:10.1093/nar/gkx247  ·  IF 18.1 · Q1 PubMed↗
  28. [28] Bell Xi Wu, Xiaozhuo Ran, Olivia Huang, Lifang Song, Vivek Philip, Adrian Sacher, Ming-Sound Tsao, Benjamin H Lok SCLC humanized mice identify T cell infiltration phenotypes in response to combination immune-radiation therapies. iScience 2026 Aug 21 doi:10.1038/nprot.2013.143  ·  IF 4.5 · Q1 PubMed↗
  29. [29] Pui Man Choy, Ho Yin Arnold Wong, Eric Kian Saik Lim, Samanjit Singh Hare, Anant Rameshchandra Chaturbhai Patel, Deborah Pencharz, Thomas Wagner Systematic review and meta-analysis of FDG PET-CT for nodal staging of part-solid lung adenocarcinomas. CHEST 2026 Aug 05 doi:10.1016/j.chest.2026.06.070  ·  IF 9.8 · Q1 PubMed↗
  30. [30] Linfeng Wu, Changhao Ren, Yifei Zhang, Gaojia Wang, Kai-Qian Zhou, Kechen Guo, Zhiwang Zhao, Dongxian Jiang, Yanbo Liu, Yuning Zhou, Yanjun Zhou, Mengting Wang, Han Ding, Yuanyuan Ruan, Pinghong Zhou, Yiqun Zhang Targeting GEM Reprograms Macrophages and Overcomes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma. Cancer Research 2026 Aug 06 doi:10.1158/0008-5472.CAN-25-5396  ·  IF 22.6 · Q1 PubMed↗
  31. [31] Taoyang Xu, Xueping Luo, Mao Lin, Jiao-Jiao Xu, Li Qiu, Huining Liu, Qier Mu, Tong Yang, Jiaxi Chen, Wangcheng He, Siyuan Ma, Shengyuan Jiang, Jing Yang, Yan He, Can-Can Zheng, Xingyang Xue, Xin Hao, Lian Zhang, Jun Liu, Bin Li, Wenwen Xu Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma. Cancer Research 2026 Aug 05 doi:10.1158/0008-5472.CAN-25-5920  ·  IF 22.6 · Q1 PubMed↗
  32. [32] Zihan Zhang, Feifei Liu, Peng Wang, Ting Wang, Xiangyu Wang, Rui Wang, Xiaodan Shi, Ruixia Zou, Ludan Jia, Xing Wei, Zhibo Li, Yankan Yu, HaiBo Sun, Dong Joon Kim, Simin Zhao, Zigang Dong Chronic Stress-Induced m7G Cap Modification of ADRB2 Dysregulates the Pentose Phosphate Pathway to Promote Esophageal Squamous Cell Carcinoma Progression. Cancer Research 2026 Aug 05 doi:10.1158/0008-5472.CAN-25-5775  ·  IF 22.6 · Q1 PubMed↗
  33. [33] Liangchao Sun, Ahmed Ghanim Glayl, Ming Zhang, Chenglong Zhao, Jialin Sun, Kaikai Zhao, Jiaxin Sun, Xue Meng ADAR1 regulates radiosensitivity in ESCC through cIAP2-NF-κB signaling and C16orf46 editing. iScience 2026 Aug 21 doi:10.1016/j.smim.2021.101474  ·  IF 4.5 · Q1 PubMed↗
  34. [34] Rajiv Sharma, Adriana Rafael, Caitlin Pailthorpe, Keshav Bhattarai, Jee-Yoong Leong, Sajid Sayed The evolution of a novel technique for treatment of intercostal hernias and restoration of costal margin rupture. Injury - International Journal of the Care of the Injured 2026 Jul 29 doi:10.1016/j.injury.2026.113531  ·  IF 2.4 · Q2 PubMed↗
生成于 2026-08-13 15:48:49 · 周界按 PubMed 入库日(edat)划分